Amylyx Pharmaceuticals (AMLX) EBITDA (2021 - 2026)

Amylyx Pharmaceuticals' EBITDA history runs 6 years deep, the most recent figure standing at -$43.8 million for Q1 2026.

• On a quarterly basis, EBITDA fell 15.81% year-over-year to -$43.8 million in Q1 2026; TTM through Mar 2026 was -$159.3 million, a 30.87% increase from a year earlier, with the FY2025 full-year figure at -$153.3 million, up 51.29% from the prior year.
• EBITDA slipped to -$43.8 million in Q1 2026 per AMLX's latest filing, from -$36.6 million in the prior quarter.
• Across five years, EBITDA topped out at $20.2 million in Q2 2023 and bottomed at -$122.1 million in Q1 2024.
• The 5-year median for EBITDA is -$42.9 million (2025), against an average of -$39.7 million.
• Across the five-year window, EBITDA soared 137.23% in 2023 and tumbled 5848.86% in 2024, its largest moves.
• Year by year, EBITDA stood at -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then plunged by 2202.07% to -$40.7 million in 2024, then grew by 9.96% to -$36.6 million in 2025, then declined by 19.6% to -$43.8 million in 2026.
• Per Business Quant, the three latest AMLX EBITDA figures stand at -$43.8 million (Q1 2026), -$36.6 million (Q4 2025), and -$36.0 million (Q3 2025).